latest-news-headlines Market Intelligence /marketintelligence/en/news-insights/latest-news-headlines/demand-will-outstrip-supply-for-roche-s-us-fda-approved-coronavirus-test-57570601 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Demand will outstrip supply for Roche's US FDA-approved coronavirus test

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Demand will outstrip supply for Roche's US FDA-approved coronavirus test

Roche Holding AG said demand will inevitably outstrip supply for its new coronavirus test, which was granted emergency authorization by the U.S. Food and Drug Administration.

The test is used on Roche's diagnostics systems, known as the cobas 6800 and the cobas 8800, which are widely available across the world. CEO Severin Schwan said the Basel, Switzerland-based pharmaceutical and diagnostics company had initially provided the test for free in January to Chinese authorities.

The test is intended for the qualitative detection of nucleic acids from the virus, or SARS-CoV-2 — which causes the respiratory disease COVID-19 — in swab samples from the pharynx of patients who meet the COVID-19 criteria for testing.

Results from the test are provided in 3.5 hours — the fastest for any available coronavirus test and can be run on the diagnostic machine at the same time as other assays, such as blood or infectious disease tests.

However, the test can only be used for the duration of its U.S. FDA emergency authorization. Amid a shortage of available tests for the coronaviruswhich was declared a pandemic by the World Health Organization on March 11 Roche said it is able to provide millions of tests and is committed to delivering as many as possible in the most affected areas within the limits of supply.

"We have robust business continuity plans and are doing everything possible to produce as many tests and products as we can during this developing situation," media spokesperson Patrick Barth said in an emailed response to S&P Global Market Intelligence. "However, at the height of any global health emergency, demand will outweigh supply."

Roche would not comment on pricing other than to say its priority is to make the tests available to those who need them.

Shares in Roche were up 4.71% to CHF280.00 at 4:19 p.m. Basel time on March 13.

SNL Image

Commenting on the global spread of the coronavirus, SVB Leerink analyst Geoffrey Porges wrote in a note that the "end-game" will in part depend on "significant technical and commercial advances by diagnostic and therapeutic companies, who hopefully get some funding and other relief from the endless criticism they have received over the last decade or so."

"No matter what we might hope or believe, COVID-19 is not going away," he said.